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Abstract 
Background and Aim: Systemic lupus erythematosus (SLE) is an autoimmune disease and human polyomavirus BK 
(BKV) can be reactivated in patients with SLE due to the changes in the immune system and use of immunosuppressive 
drugs. In this study, we evaluated the prevalence of BKV infection among patients with SLE referred to Golestan 
hospital in Ahvaz, Iran between April 2013 to June 2016. 
Methods: In this cross-sectional study we studied 75 individuals including 40 patients with SLE and 35 normal 
individuals. Urine and blood samples were taken and DNA was extracted from urine and plasma. Polymerase Chain 
Reaction (PCR) test was used to detect the BKV genome and positive samples were sequenced to confirm BKV. 
BioEdit software and MEGA 6.0 software were used for phylogenetic analysis to assemble the viral genome. A 
phylogenetic tree was constructed by neighbor-joining analysis with 1,000 replicates of the bootstrap resampling test 
using Mega 6.0. Statistical analysis was done by SPSS version 22.  
Results: Among the 40 patients, 2 (5%) were men and 38 (95%) were women.  The mean age of the patients was 
39±10 years. 2.5% of plasma from patients with SLE were positive for BKV but none of the controls were positive in 
this regard.0% of control groups (p=0.346). Whereas in urine samples, 17.5% and 11.4% (p=0.458) of patients and the 
control group, were positive for BKV, respectively. However, there was no statistically significant difference between 
the patients and controls. 
Conclusion: BKV reactivation occurs in 17.5% of patients with SLE during immunosuppression therapy. Therefore, 
more studies on BKV DNA by highly sensitive molecular assays in Patients with SLE seem to be necessary. 
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Introduction 
BK virus (BKV) and JC virus (JVC) are the two 
most commonly known human polyomaviruses, 
which were first described in the 1971s (1, 2). The 
BKV is a non-enveloped virus and it is 
approximately 45 nm in diameter. The virion 
contains a circular double-stranded DNA of 
approximately 5kbp (3, 4). The genome packed into 
particles is known to code for three structural 
proteins, such as viral capsid protein 1(VP1), VP2, 
and VP3 that VP1 is the major capsid protein (5). 
BKV is classified into four major subtypes 
including I (most frequent), II, III, and IV that 
variations in the DNA sequence of the VP1 gene 
are based on this division (6, 7).  
Serological studies have shown that infection 
prevalence is widespread and occurs early in life. 
The BKV seropositivity reaching 90% in children 
aged 5 to 9 (8) and it’s as high as around 90 % in 
healthy adults (9).  The BKV DNA has been found 
in 30 to 50% of normal renal tissues and 40% of 
ureters (10). Systemic lupus erythematous (SLE) is 
an immune-mediated disease disorder in which the 
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patients experience several complications such as 
renal problems (11). The hormonal and 
immunological changes, inflammation, and 
infections can exacerbate the immune system 
responses and increase the risk of SLE especially in 
pregnancy (12). The immune system change in 
autoimmune diseases such as SLE and the use of 
immunosuppressive drugs have been confirmed 
(13). In SLE disease, BKV which is linked with 
several implications especially in renal such as 
ureteral stenosis, hemorrhagic cystitis, and 
nephropathy, can be reactivated and implicated in 
the disease severity. Furthermore, the virus is 
associated with pneumonitis, retinitis, liver disease, 
and meningoencephalitis (14, 15). Asymptomatic 
BK viruria occurs in up to 60% of 
immunocompromised patients (16). Use of 
immune-modulatory drugs seems to increase the 
prevalence of BKV to 63% in Patients with SLE.  
However, the prevalence rate before starting 
Natalizumab and Rituximab seems to be 8.3% and 
27% respectively (17). BKV prevalence reported in 
1 to 15.7% of plasma and 41.8% of urine samples 
of kidney transplanted patients in Iran (18). In this 
study we evaluated the existence of BKV in patients 
with SLE in Ahvaz a city at south west of Iran 
between April 2013 and June 2016 and compared 
with a control group to make a comparison and find 
out if SLE patents are more vulnerable to BKV. 
Methods 
Study design 
In this study 75 individuals including 40 patients 
with SLE that were selected by rheumatologists 
based on clinical and laboratory characteristics from 
April 2013 to June 2016 in Golestan Hospital, 
Ahvaz city were studied and 35 healthy individuals 
were selected as a control group. About 50 mL 
urine was collected in a falcon that contained 
0.5 mL of 0.5 M EDTA, pH 8.0. Each sample was 
centrifuged at 3000 rpm for 5 minutes and the pellet 
was kept at -80°C until further analyses. Also, 3–
5 mL of blood was collected in single EDTA tubes. 
Specimens were centrifuged for 5 min at 3000 rpm. 
Plasma samples were collected and then stored at -
80◦C until further analyses. 
Extraction of DNA from plasma and urine 
DNA was extracted from 200 μL of urine and 
plasma specimens using High Pure Viral Nucleic 
Acid Kit (Roche, Germany) according to 
manufacturer’s instructions. The extracted DNA 
was stored at -20°C till used. 
PCR 
The following primers were used for the detection 
of BKV DNA: 
Forward primer, 327-1PST (5′-
GCCTGCAGCAAGTGCCAAAACTACTAAT-3′; 
nt 1630–1649); Reverse primer, 327-2HIN (5′- 
GCAAGCTTGCATGAAGGTTAAGCATGC-3′; nt 
1956–1937) (19).PCR was performed with 25 µL 
volume, containing the 3 μL extracted DNA, 0.5 µL 
from each primer, 12.5 µL amplification premix 
(PCRBIO Taq Mix Red 2x) and 8.5µl distilled 
water. The reaction mixture was subjected to a 
thermal cycler (PeQlab, Germany) with the 
following program: 1 cycle with an initial 
denaturation at 95°C for 2 minutes, followed by 40 
cycles, 95°C for 30 seconds, 55°C for 30 seconds, 
72°C for 30 seconds, and final extension at 72°C 
for 5 minutes. All reactions were performed in the 
presence of negative and positive controls. The 
342 bp PCR product was subjected to 
electrophoresis on a 1.7% agarose gel supplemented 
with DNA safe Stain (Cinna Gen) and visualized 
using a UV transilluminator.To determine the BKV 
subtype, positive samples were sequenced by Noor 
gene laboratory, Ahvaz, Iran.  
Phylogenetic study 
All sequenced viral DNA fragments were 
assembled using the BioEdit software. The MEGA 
6.0 software was used for phylogenetic analysis. 
The partial nucleotide sequences of VP1 (342 nt) 
aligned with the different BKV genotypes isolated 
from different regions of the world by CLUSTAL 
W. Phylogenetic trees were constructed by 
neighbor-joining analysis with 1,000 replicates of 
the bootstrap resampling test using Mega 6.0. 
Ethical consent 
The project was approved by the ethics committee 
of Ahvaz Jundishapur University of Medical 
Sciences, Ahvaz Iran. All of the individuals 
included in the study were orally informed about 
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the purpose of the study and invited to participate. 
Each patient gave informed consent. 
Statistical analysis 
Data analysis was performed using the Statistical 
Package for the Social Sciences 22.0 (SPSS Inc., 
Chicago, IL, USA). The Chi-Square test was used 
to calculate. p<0.05 was accepted as significant. 
Results 
From the total of 40 patients, 2 (5%) were males 
and 38 (95%) were females. In the control group, 
all individuals (100%) were female. The mean age 
of the patients was 39±10 years. The mean age of 
the control group was 41±8 years. All individuals 
were between 19 and 63 years old.  
Overall, among our 75 cases, we found BKV 
viremia in one case (2.5%) and viruria in 11 
(12.9%). One out of 40 patients was positive for BK 
virus in plasma samples (2.5%). In the control 
group, no positive cases were detected. The 
prevalence of the BK virus was not significant 
between both groups (p= 0.346). 
Seven out of 40 (17.5%) patient’s urine samples 
were positive for BKV. In the control group, 4 out 
of 35 (11.4%) cases were positive and there was no 
significant difference (p= 0.458). The above items 
are shown in Table 1. Four out of 12 positive 
samples were "subtype I" BKV base on Sanger 
sequencing technique (Figure 1). 
 
Table 1: BK viremia and viruria in 40 patients with systemic lupus erythematosus and 35 healthy individuals 
 
 
Figure 1. A phylogenic tree was constructed with neighbor-joining method using the partial sequences 
of VP1 region of BKV, reference sequences were retrieved from GenBank with their Accession 
Numbers. The results of the phylogenetic tree show the isolated Iranian with circular black are clusters 
with BKV 1b accession number AB369232.1 isolated from the USA. The accuracy was assessed by 
1000 bootstrap replicates. Scale bar=0.01 
p-value BK DNA in urine p-value BK DNA in plasma Group 
 
0.458 
N= 7 (17.5%) Positive  
0.346 
N=1 (2.5%) Positive Patients 
N= 40 
N= 33 (82.5%) Negative N= 39 (97.5) Negative 
N= 4 (11.4%) Positive N= 0 (0%) Positive Control 
N= 35 N= 31 (88.6%) Negative N= 35 (100%) Negative 
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Discussion 
The human polyomaviruses BKV are the most 
prevalent viruses in the human population 
worldwide (20). The polyomavirus infection rates 
might be variations between different countries 
(21). There is a significant association between the 
BKV infection and SLE disease development (3). 
Impairment of the human immune system due to the 
use of immunosuppressive drugs or deregulated 
immune responses are the potential risk factors for 
BKV reactivation in Patients with SLE (22). 
Immunosuppressive drugs, especially cyclosporine 
A, have been reported to increase Transforming 
Growth Factor (TGF)- β1 expression, which in turn 
leads to immune suppression. Studies indicated that 
TGF- β1can enhance BKV reactivation in renal 
tubular cells in cell culture. In patients with SLE’ 
immune complexes in serum (anti-double-stranded 
DNA-dsDNA) often correlated with inflammation 
of the kidneys and leads to lupus nephritis (23). T 
antigen is the BK virus' transcription factor and is a 
DNA-binding protein that binds to both viral and 
host cell DNA (24). Therefore, the role of BKV in 
Patients with SLE can be examined in two aspects. 
1) BKV can lead to induced lupus syndrome or 2) 
the use of immunosuppressive agents and biological 
therapies that can increase the reactivation of BKV 
infection and affect the prognosis and treatment of 
SLE. BKV is detectable in the blood (whole blood, 
plasma, serum), urine, renal tissue via detection of 
viral cytopathic effect (decoy cells), NAT, and 
BKV specific antibody (25). Usually, the first 
indication of the reactivation of BKV is BK viruria 
which subsequently occurs after several weeks of 
the BK viremia (7). The prevalence of BK in renal 
transplant recipients is approximately 1% to 10% 
and viruria and viremia precede nephritis might 
happen as early as 6 days and up to 5 years 
posttransplant. Viruria and viremia can be detected 
weeks to months before a detectable increase in 
serum creatinine levels among transplant candidate 
(26). 
In Japan, Taguchi et al. showed the presence of 
BKV antigen via indirect immunofluorescence 
technique in the urine of two patients with SLE 
(27). In Norway, Sundsfjord et al. analyzed 44 
DNA extracted from urine samples using the PCR 
method in patients with SLE and healthy 
individuals. Their result indicated that 7 (16%) of 
44 patients and 0 (0%) of 88 matched healthy 
controls were positive for BKV DNA. About 26 % 
of those patients continued to have persistent or 
recurrent BK viruria at 1–3 years follow-up (28). 
This study is parallel with our study and the results 
are strikingly resemblance to ours.  
In another study in Norway, Bendiksen et al. used 
PCR methods to examine urine samples of 19 
patients with SLE and they reported 17(89.4%) 
positive cases for BKV. During a year follow-up 
study, BKV was detected in 48 (48%) of 100 
specimens (29). In Italy, Colla et al. confirmed the 
presence of BKV DNA by semi-nested PCR in 
serum and urine specimens of 40 SLE nephritis 
patients and 29 healthy controls. In this study, BKV 
DNA was detected in 15% and 13.8% of serum 
samples of patients and the control group, 
respectively, as well as, 32 % and 17.2% of urine 
samples (30). In Taiwan, LU et al. was tested the 
urine samples of 95 patients with SLE and 32 
healthy individuals for BKV DNA by real-time 
PCR. The results of this study showed a high 
prevalence rate of BKV viruria in patients (71.6%) 
than in the control group (18.6%). Their results 
suggest the possibility of immunosuppression in 
BKV reactivation in the urinary system. They have 
also observed a significant correlation between the 
reactivation of BKV and platelet count (31). In 
Thailand, Rianthavorn et al. indicated 32% (16 of 
50) of urine samples of pediatric patients with SLE 
were positive for BKV DNA via nested PCR (32). 
In the USA, Gupta et al. reported the prevalence of 
BKV in children with SLE was 3.1% (1 of 32) for 
BK viruria and 6.2% (2 of 32) for BK viremia (17). 
This controversy may come from the differences in 
the genetic background of the patients, differences 
in the age of patients, differences in the sample size, 
and differences in the diagnostic methods. 
However, this study has several limitations. Firstly, 
since different phases of SLE disease and its 
treatment can cause a major susceptibility to 
develop BKV infection and virus reactivation 
occurs during impaired immune conditions, it was 
better to take several samples from the patients 
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during the treatment course. Secondly, the number 
of cases tested in this study was low; hence, further 
studies with larger populations are needed to 
understand the impact of immunosuppression in 
patients with SLE and the risk for BKV infections. 
Thirdly, the use of more sensitive methods for 
detecting such as nested PCR or Real-time PCR is 
recommended. Lastly, the measurement of urea as 
an important potential inhibitor of the PCR and 
assessment of routine viral load monitoring is 
suggested for future studies.  
Conclusion 
In the present study, the prevalence of BKV was 
determined in serum and urine samples using PCR. 
Here, the BKV viremia was observed among 2.5% 
versus 0% and BK viruria in 17.5% versus 11.4% 
of the patients and control groups, respectively. Our 
results show that the all our subtype is subtype I of 
BKV which is in accordance with other reports. 
Finally, this study showed a low rate of BK viremia 
and viruria in patients with SLE, and prevalence 
data in those patients did not significantly differ 
from the control group. Since BKV is closely linked 
to renal failure, more comprehensive studies are 
needed to prove it in Patients with SLE. 
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